Compare ZYME & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | PNTG |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2022 | 2019 |
| Metric | ZYME | PNTG |
|---|---|---|
| Price | $22.81 | $41.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $38.90 | $37.00 |
| AVG Volume (30 Days) | ★ 531.8K | 326.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 20.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | $105,965,000.00 | ★ $947,705,000.00 |
| Revenue This Year | $183.10 | $24.72 |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ N/A | $165.88 |
| Revenue Growth | ★ 38.87 | 36.31 |
| 52 Week Low | $11.86 | $21.74 |
| 52 Week High | $29.75 | $42.55 |
| Indicator | ZYME | PNTG |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 63.74 |
| Support Level | $22.20 | $28.25 |
| Resistance Level | $23.66 | N/A |
| Average True Range (ATR) | 0.92 | 1.66 |
| MACD | -0.30 | -0.14 |
| Stochastic Oscillator | 1.07 | 63.58 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.